摘要
目的分析急性冠脉综合征患者在他汀治疗未达标的基础上应用依洛尤单抗的降脂疗效。方法回顾性收集自2019年1月至2020年9月于阜外华中心血管病医院就诊的174例他汀治疗未达标的急性冠脉综合征患者的临床资料,根据来院后是否应用依洛尤单抗分为依洛尤单抗组(124例)和他汀组(50例),依洛尤单抗组在他汀类药物(每日口服阿托伐他汀20 mg或瑞舒伐他汀10 mg)基础上联用依洛尤单抗(皮下注射140 mg,每2周1次);他汀组应用他汀类药物(每日口服阿托伐他汀20 mg或瑞舒伐他汀10 mg),收集两组患者12周后来院复查的抽血化验情况,包括总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白A1(ApoA1)、载脂蛋白B(ApoB),并进行统计分析。结果两组患者治疗前的TC、TG、HDL-C、LDL-C、ApoA1、ApoB水平之间差异无统计学意义(P>0.05);治疗12周后复查,TC、HDL-C、LDL-C、ApoB之间差异有统计学意义(P<0.01);TG、ApoA1之间差异无统计学意义(P>0.05);两组患者治疗前的ApoB/ApoA1比值之间的差异无统计学意义(P>0.05),治疗后两组患者的ApoB/ApoA1比值之间的差异有统计学意义(P<0.01)。结论依洛尤单抗对急性冠脉综合征患者有降脂效果,与他汀类药物联用可明显降低LDL-C水平,对其他胆固醇同样有正向调节作用。为应用他汀类药物降脂效果不佳的急性冠脉综合征患者提供了降脂治疗的新选择。
Objective To analyze the lipid-lowering effect of evolocumab in patients with acute coronary syndrome who have not reached the standard on the basis of statin treatment.Methods The clinical datas of 174 patients with acute coronary syndrome who were treated at the Fuwai Central China Cardiovascular Hospital from January 2019 to September 2020 were retrospectively collected.According to whether they were treated with evolocumab after admission,they were classified as evolocumab group(124 cases)and statin group(50 cases).Evolocumab group was given evolocumab(140 mg subcutaneously,once every 2 weeks)on the basis of statins(atorvastatin 20 mg or rosuvastatin 10 mg everyday).Statin group was given statins(atorvastatin 20 mg or rosuvastatin 10 mg everyday).The blood test results of the two groups of patients who came to the hospital after 12 weeks were collected and statistically analyzed,including total cholesterol(TC),triglycerides(TG),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),apolipoprotein A1(ApoA1),apolipoprotein B(ApoB).Results There were no significant differences in the levels of TC,TG,HDL-C,LDL-C,ApoA1 and ApoB between the two groups of patients before treatment(P>0.05).Recheck after 12 weeks of treatment,the levels of TC,HDL-C,LDL-C and ApoB were significant differences between the two groups(P<0.01).There were no significant differences in the levels of TG and AopA1 between the two groups(P>0.05).There was no significant difference in the ratio of ApoB/ApoA1 between the two groups of patients before treatment(P>0.05).After treatment,the difference in the ratio of ApoB/ApoA1 between the two groups of patients was statistically significant(P<0.01).Conclusion Evolocumab has a lipid-lowering effect on patients with acute coronary syndromes.Combined with statins can significantly reduce the level of LDL-C,and it also has a positive regulatory effect on other cholesterols.It provides a new choice of lipid-lowering therapy for patients with acute coronary syndrome who ha
作者
王星星
王阳阳
高传玉
王宪沛
高晨曦
张优
WANG Xingxing;WANG Yangyang;GAO Chuanyu;WANG Xianpei;GAO Chenxi;ZHANG You(Department of Cardiovascular Medicine,Zhengzhou University People’s Hospital/Henan Provincial Peoples’s Hospital,Zhengzhou 450000,China;b.Department of Obstetrics and Gynecdogy,Zhengzhou University People’s Hospital/Henan Provincial Peoples’s Hospital,Zhengzhou 450000,China;Coronary Heart Disease ward 1,Fuwai central China Cardiovascular Hospital,Zhengzhou 450000,China;Henan Provincial Cardiovascular Disease Epidemiology Center,Fuwai central China Cardiovascular Hospital,Zhengzhou 450000,China)
出处
《河南医学研究》
CAS
2021年第24期4421-4424,共4页
Henan Medical Research
基金
国家重点研发项目(2018YFC0114500)。
